Search International and National Patent Collections

1. (WO2018142393) N1 -(4-(5-(CYCLOPROPYLMETHYL)-1 -METHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAKI INHIBITORS FOR TREATING CANCER

Pub. No.:    WO/2018/142393    International Application No.:    PCT/IL2018/050100
Publication Date: Fri Aug 10 01:59:59 CEST 2018 International Filing Date: Wed Jan 31 00:59:59 CET 2018
IPC: C07D 401/04
C07D 403/04
C07D 417/04
A61K 31/4439
A61K 31/506
A61K 31/4155
A61K 31/427
A61P 35/00
Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
Inventors: LI, Dansu
SNIR-ALKALAY, Irit
VACCA, Joseph
BEN-NERIAH, Yinon
VENKATAC-IALAM, Avanthika
Title: N1 -(4-(5-(CYCLOPROPYLMETHYL)-1 -METHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAKI INHIBITORS FOR TREATING CANCER
Abstract:
The present invention provides pyrazole derivatives of Formula (I), and in particular N1-(4-(5-(cyclopropylmethyl)-1-methyl-lH-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as casein kinase 1 (CK1) and/or interleukin 1 receptor associated kinase 1 (IRAKI) inhibitors for treating cancer, inflammatory and immune related disorders.